$8.26 Million in Sales Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter

Wall Street analysts expect Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to announce $8.26 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Conatus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $8.79 million and the lowest estimate coming in at $7.50 million. Conatus Pharmaceuticals posted sales of $9.74 million during the same quarter last year, which suggests a negative year-over-year growth rate of 15.2%. The company is scheduled to issue its next earnings results on Wednesday, May 1st.

On average, analysts expect that Conatus Pharmaceuticals will report full year sales of $32.85 million for the current fiscal year, with estimates ranging from $24.56 million to $40.00 million. For the next financial year, analysts anticipate that the business will report sales of $18.25 million, with estimates ranging from $1.50 million to $35.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Friday, March 8th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Conatus Pharmaceuticals had a negative return on equity of 82.49% and a negative net margin of 53.62%. The business had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $8.63 million.



CNAT has been the subject of several research reports. Zacks Investment Research reaffirmed a “hold” rating and set a $1.50 target price on shares of Conatus Pharmaceuticals in a research note on Monday, December 31st. SunTrust Banks cut Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. ValuEngine raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. HC Wainwright decreased their target price on Conatus Pharmaceuticals from $14.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, March 11th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Wednesday, February 13th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $5.12.

Several hedge funds and other institutional investors have recently made changes to their positions in CNAT. Two Sigma Investments LP lifted its holdings in shares of Conatus Pharmaceuticals by 761.1% during the fourth quarter. Two Sigma Investments LP now owns 250,085 shares of the biotechnology company’s stock valued at $433,000 after purchasing an additional 221,044 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Conatus Pharmaceuticals by 13.4% during the third quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock valued at $9,419,000 after purchasing an additional 191,287 shares during the last quarter. Hikari Power Ltd purchased a new stake in shares of Conatus Pharmaceuticals during the fourth quarter valued at $289,000. Sofinnova Investments Inc. lifted its holdings in shares of Conatus Pharmaceuticals by 18.4% during the fourth quarter. Sofinnova Investments Inc. now owns 638,197 shares of the biotechnology company’s stock valued at $1,104,000 after purchasing an additional 99,282 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Conatus Pharmaceuticals by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 208,346 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 33,827 shares during the last quarter. 27.41% of the stock is owned by institutional investors and hedge funds.

Shares of CNAT stock opened at $0.80 on Tuesday. Conatus Pharmaceuticals has a fifty-two week low of $0.73 and a fifty-two week high of $6.74. The stock has a market cap of $36.92 million, a P/E ratio of -1.36 and a beta of 3.27.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Featured Article: What is a Market Correction?

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.